Skip to main content
OpenTrials
Completed

NCT Number: NCT04848194

Pleiotropic Role of TRPV1 in Psoriasis Inflammation

Widely expressed in the sensory nerve endings of the skin, Transient Receptor Potential Vanilloid 1 (TRPV1) is a receptor that plays an important role in the perception of pain and pruritus but also in skin inflammation, primarily by inducing the local release of several neuropeptides.

Although the mechanisms by which TRPV1-sensitizing inflammatory mediators in damaged skin have received considerable attention, the role of TRPV1 in psoriasis has so far been little explored.

However, two studies have reported that ablation of sensory nerves expressing TRPV1 reduced psoriasiform skin inflammation, demonstrating the neuronal contribution to inflammation in psoriasis.

However, the expression of TRPV1 is not limited to neurons alone. TRPV1 is also expressed by epidermal keratinocytes and skin microvessels.

For example, in 2018, transcriptomic analysis of psoriatic patient skins (by definition devoid of neuron nuclei) revealed that TRPV1 expression was increased in the skin of psoriatic patients suffering from itching (pruritus).

Regarding human keratinocytes, it is recognized that the activation of TRPV1 present on their surface induces the release of pro-inflammatory factors such as cyclooxygenase-2. In addition, the investigators have demonstrated that TRPV1 has a pivotal role in the keratinocyte production of inflammatory mediators, which is mediated by the protease-activated receptor-2 (PAR-2). However, the role of vascular TRPV1 in inflammation is not described.

The investigators hypothesize that in addition to neuronal TRPV1, non-neuronal TRPV1 receptors of non-neuronal cells (keratinocytes and endothelial cells) may be involved in the vicious circle of the inflammatory process characteristic of psoriasis. Putting TRPV1 at the center of the deregulation of the homeostatic balance including epithelial, neuronal and vascular inflammation in psoriasis is totally innovative.

Completed

Looking for future studies?

Notify Me

Key information

Age range

18 year and older

Sex eligibility

All sexes

Study type

Interventional

Phase

Not applicable

Primary location

TALAGAS

Brest, 29200, France

About this study

Each patient will have a sample taken in the dermatology department:

  • 4 skin biopsies
  • A blood sample.

Patients with psoriasis will be recruited from the dermatology department. There will be no further visits, so the duration of the study is 1 day.

The samples taken will be used to determine the pleiotropic role of TRPV1 in Psoriasis Inflammation.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Patients over 18 years old with psoriasis, with or without itching (pruritus).
  • Presence of lesional and non lesional zones, in unexposed areas and surface area (outside the face and folds) large enough to allow the biopsies to be performed
  • Patients who have given written consent

Exclusion criteria

  • Patients with physical or psychological incapacity to sign consent
  • Patients not covered by the Social Security system
  • Patients with topical treatments for psoriasis,
  • Patients with systemic treatments for psoriasis,
  • Patients allergic to lidocaine
  • Patients over the age of majority who are subject to legal protection or who are unable to give consent
  • Patients deprived of liberty by a judicial or administrative decision
  • Pregnant women, parturients and breastfeeding mothers

Treatment and study plan

skin biopsy and blood sampling

Procedure
  • 4 skin biopsies outside the face under local anesthesia: 2 in damaged zone, 2 in non-damage zone.
  • A blood sample

Primary outcomes

  1. Role of TRPV1 receptors expressed by sensory neurons and non-neuronal cells (keratinocytes and endothelial cells) in the inflammatory process characteristic of psoriasis.

    Time frame: 1 day

    Density of intra-epidermal nerve fibers expressing the TRPV1 receptor

Secondary outcomes

  1. Density changes of intra-epidermal nerve fibers expressing neuropeptides

    Time frame: 1 day

    Density of intra-epidermal nerve fibers expressing neuropeptides by immunohistochemistry

  2. Changes in endothelial cell density between an injured and an uninjured area of the same patient

    Time frame: 1 day

    quantification of the transcriptional and protein expression of TRPV1

  3. Changes in endothelial cell density between an injured and an uninjured area of the same patient

    Time frame: 1 day

    quantification of TRPV1 activity

  4. Changes in endothelial cell density between an injured and an uninjured area of the same patient

    Time frame: 1 day

    Identification and quantification of the blood cytokine profile

  5. Changes in the density of keratinocytes and their contacts with nerve fibers

    Time frame: 1 day

    Number and distribution of contacts between keratinocytes and nerve fibers

Sponsors and collaborators

Lead sponsor

University Hospital, Brest

Other

Registry information

Acronym: TRIP

Important dates

Study start
2021
Primary completion
2024
Study completion
2024
First posted
Apr 19, 2021
Registry last updated
Mar 28, 2025

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.